Letters to the Editor

Modern Pathology (2008) 21, 1054; doi:10.1038/modpathol.2008.18

To the editor: Although the existence of the CpG island methylator phenotype (CIMP) in colorectal cancer may be controversial, we were disappointed that the review by Agrawal *et al* of DNA methylation in breast and colorectal cancer¹ did not cite recent studies that support CIMP. Although all studies of colon cancer have not reported the same associations with CIMP, there has been remarkable unanimity with respect to a very strong relationship with the *BRAF* V600E mutation. This relationship is independent of microsatellite instability and has been observed using different techniques and CpG islands to evaluate CIMP.^{2–4} Also, a significant relationship between CIMP and cigarette smoking independent of microsatellite instability has been seen;⁵ this relationship to an epidemiologic risk factor also supports CIMP as a true phenotype.

With regard to hereditary nonpolyposis colorectal cancer (HNPCC), it is somewhat misleading to state that ‘... aberrant methylation of the mismatch repair genes, ... hMLH1 or hMLH2, are the basis for the cancer (*in hereditary non-polyposis colorectal cancer*).’ The overwhelming percentage of cases of HNPCC is the result of a germ-line mutation and a subsequent somatic second hit (usually mutation) in one of the mismatch repair genes; germ-line methylation is an extremely rare cause of this syndrome.

Wade S Samowitz¹ and Shuji Ogino²

¹Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT, USA and

²Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

References

- 1 Agrawal A, Murphy RF, Agrawal DK. DNA methylation in breast and colorectal cancers. *Mod Pathol* 2007;20: 711–721.
- 2 Samowitz WS, Albertsen H, Herrick J, *et al*. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. *Gastroenterology* 2005;129:837–845.
- 3 Weisenberger DJ, Siegmund KD, Campan M, *et al*. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with *BRAF* mutation in colorectal cancer. *Nat Genet* 2006;38:787–793.
- 4 Ogino S, Kawasaki T, Kirkner GJ, *et al*. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. *J Mol Diagn* 2007;9:305–314.
- 5 Samowitz WS, Albertsen H, Sweeney C, *et al*. Association of smoking, CpG island methylator phenotype, and V600E *BRAF* mutations in colon cancer. *J Natl Cancer Inst* 2006;98:1731–1738.

Modern Pathology (2008) 21, 1054–1055; doi:10.1038/modpathol.2008.21

In reply: We thank Dr Samowitz and Dr Ogino for their letter in response to our paper on DNA methylation in breast and colorectal cancer.¹ Colorectal cancers can evolve through multiple pathways that are primarily defined on the basis of microsatellite instability and CIMP status.² In our article, we briefly discussed the potential role of CIMP in the diagnosis of colorectal cancer. Based on the published reports cited in our article, there is still controversy on the association of CIMP with colorectal cancer. Since the publication of our article, we have come across the published reports of Dr Ogino and co-workers on molecular features of CIMP tumors, suggesting the classification of colorectal cancers into three subgroups based on CIMP status: Non-CIMP, CIMP-low, and CIMP-high.³ In our article, we had mentioned about the CIMP(+) and CIMP(–) colorectal tumors. However, to the best of our knowledge, there is no strong evidence to

support the existence of CIMP-low. Furthermore, the origin of CIMP-low tumors is not known. It is our understanding that only a subgroup of colorectal cancers, CIMP-high, show a correlation with *BRAF* V600E mutation, suggesting that CIMP-high colorectal cancers might originate from serrated polyps. But, there could be both microsatellite unstable-CIMP+ and microsatellite stable-CIMP+ subsets of colorectal cancer. We do not disagree with Dr Samowitz and Dr Ogino that CIMP could be a true phenotype of a subset of colorectal cancers. Thus, there are clearly distinct subclasses of colorectal tumors based on molecular heterogeneity. Many recent reports support this view.^{3–4} Nonetheless, as pointed out in a recent commentary, there are more questions than the answers in this complex area of CIMP and colon cancer.⁵

We are also aware of the association between the exposure to epimutagens, including tobacco smoke,

and aberrant DNA methylation. This is especially true in non-small cell lung carcinomas. However, an association of smoking, CpG island methylator phenotype, and C600E BRAF mutations in colon cancer does not necessarily establish cause and effect relationship. Thus, cigarette smoking could be only an inciting factor in the development of colon cancers in those subjects who have pre-existing genetic defects, and both genetic and epigenetic abnormalities that accumulate over the years could be responsible for the development of colon cancers.

In regard to the HNPCC, we referred to the findings of Gazzoli *et al.*,⁶ who found a direct association between the methylation of the region of *MLH1* and the silencing of the gene in HNPCC. In a subset of sporadic colorectal cancers, high level of microsatellite instability is caused by the inactivation of the mismatch repair gene *MLH1* due to promoter methylation. We agree that in HNPCC, which also show high level of microsatellite instability, inactivation of mismatch repair results primarily from germ-line mutations. However, *MLH1* promoter methylation has also been found in a subset of HNPCC, and this was inversely associated with loss of heterozygosity.⁷ Chan *et al.*⁸ reported a family with inheritance, in three successive generations, of germ-line allele-specific and mosaic hypermethylation of the *MSH2* gene, without evidence of DNA mismatch repair gene mutation. In this family, three siblings carrying the germ-line methylation developed early-onset colorectal or endometrial cancers, all with microsatellite instability and *MSH2* protein loss.⁸ This suggests that promoter hypermethylation or point mutation could be responsible, at least in some cases, for the somatic loss of the mismatch repair genes, *MLH1* or *MLH2* in HNPCC.

**Anshu Agrawal, Richard F Murphy and
Devendra K Agrawal**

*Department of Biomedical Sciences,
Creighton University School of Medicine,
Omaha, NE, USA*

References

- 1 Agrawal A, Murphy RF, Agrawal DK. DNA methylation in breast and colorectal cancers. *Mod Pathol* 2007;20:711–721.
- 2 Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. *Histopathology* 2007;50:113–130.
- 3 Ogino S, Kawasaki T, Kirkner GJ, *et al.* Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. *Gut* 2007;56:1564–1571.
- 4 Shen L, Toyota M, Kondo Y, *et al.* Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. *Proc Natl Acad Sci USA* 2007;104:18654–18659.
- 5 Grady WM. Commentary: CIMP and colon cancer gets more complicated. *Gut* 2007;56:1498–1500.
- 6 Gazzoli I, Loda M, Garber J, *et al.* A hereditary non-polyposis colorectal carcinoma case associated with hypermethylation of the *MLH1* gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. *Cancer Res* 2002;62:3925–3928.
- 7 Ollikainen M, Hannelius U, Lindgren CM, *et al.* Mechanisms of inactivation of *MLH1* in hereditary nonpolyposis colorectal carcinoma: a novel approach. *Oncogene* 2007;26:4541–4549.
- 8 Chan TL, Yuen ST, Kong CK, *et al.* Heritable germline epimutation of *MSH2* in a family with hereditary nonpolyposis colorectal cancer. *Nat Genet* 2006;38:1178–1183.